Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 5,918 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: mRI Clear all

Conditions: Coma, Wounds and Injuries
Interventions: Cervical Spine Clearance; Other
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: Not listed
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Chemotherapy, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Monitoring, Positron Emission Tomography, Surveillance, Tremelimumab; Drug · Biological · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Goodyear, Arizona • Corona, California • Duarte, California + 10 more

Conditions: Metastatic Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v8, Metastatic Malignant Neoplasm in the Peritoneum
Interventions: Cisplatin, Hyperthermic Intraperitoneal Chemotherapy, Nab-paclitaxel, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Post Traumatic Stress Disorder, PTSD
Interventions: TMS-fMRI; Device
Lead sponsor: Allyson Rosen; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions: Nitrous Oxide, Placebo gas, MRI; Drug · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Duarte, California • Irvine, California • La Jolla, California + 5 more

Conditions: Cardiovascular Disease
Interventions: Not listed
Lead sponsor: Essentia Health; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: Amyloidosis, Transthyretin Amyloidosis
Interventions: 124I-Evuzamitide; Diagnostic Test
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Rebif, Tecfidera; Drug
Lead sponsor: IMS HEALTH GmbH & Co. OHG; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Birmingham, Alabama • Colorado Springs, Colorado • Savannah, Georgia + 19 more

Conditions: Air Trapping, Emphysema, Hyperinflation
Interventions: Hyperpolarized Xenon MRI, Apreo BREATHE Airway Scaffold; Drug · Device
Lead sponsor: Apreo Health, Inc.; Industry
Eligibility: 40 Years to 84 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Birmingham, Alabama • Kansas City, Kansas

Conditions: Brain Metastases, Brain Metastases, Adult, Brain Cancer
Interventions: 18F fluciclovine; Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant, Multiple System Atrophy, Parkinson Variant (Disorder), Multiple System Atrophy (MSA) With Orthostatic Hypotension
Interventions: [F-18]PBR06, Verdiperstat; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liver Cancer
Interventions: bevacizumab, dexamethasone, floxuridine, protein expression analysis, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging; Biological · Drug · Genetic + 2 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2024
U.S. locations: 2
States / cities: New York, New York

Conditions: Magnetic Resonance Imaging
Interventions: Gadoterate (Dotarem/Clariscan), Gadobutrol (Gadavist/Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York • Hershey, Pennsylvania + 1 more

Conditions: Intractable Epilepsy
Interventions: Observation; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 0 Days to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers, Alcohol Drinking Related Problems, Alcohol-Related Disorders
Interventions: Real time fMRI neurofeedback; Behavioral
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Questionnaires, Electroencephalography (EEG), Magnetic Resonance Imaging (fMRI, Meditation Classes; Behavioral · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma, Leukemia, Myeloma, Lung Cancer
Interventions: MyoStrain®; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Central Nervous System Neoplasm, Solid Neoplasm
Interventions: Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Pharmacological Study, Trebananib; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 21
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 16 more

Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, CXCR1/2 Inhibitor SX-682, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Biopsy Procedure; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Pembrolizumab; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • Mineola, New York • New York, New York + 2 more

Conditions: Left Branch Bundle Block, RV - Right Ventricular Abnormality
Interventions: Pacemaker Interrogation and Electrocardiogram (ECG):, Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR, Continuous pacemaker telemetry (CPT); Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Neoplasms of the Prostate
Interventions: AuroShell particle infusion; Device
Lead sponsor: Nanospectra Biosciences, Inc.; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 5 more

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Cervical Spine Clearance in Obtunded Trauma Patients

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

Targeting the Default Mode Network: A TMS-fMRI Study

NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

St. Mary's Duluth Clinic (SMDC) Pacemaker Magnetic Resonance Imaging (MRI) Study

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

Xenon MRI to Evaluate Changes to Lung Function Following Bronchoscopic Treatment of Air Trapping in Emphysema

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation

A Response Modulation Hypothesis of Socioemotional Processing Associated With Alcohol Use Disorder

Effects of Meditation on Cognitive Function and Quality of Life

PROactive Evaluation of Function to Avoid CardioToxicity

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Functional Outcomes in CondUction System Pacing and Right Ventricular Synchrony (FOCUS-Right)

An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression